Smith Paul F
University of Otago, Department of Pharmacology & Toxicology, School of Medical Sciences, Dunedin, New Zealand.
Expert Rev Neurother. 2007 Sep;7(9):1157-63. doi: 10.1586/14737175.7.9.1157.
Recent years have seen a dramatic increase in the number of clinical trials investigating the potential efficacy of medicinal cannabinoids for the symptomatic treatment of chronic pain and spasticity in multiple sclerosis (MS). A number of different cannabinoids have been used, including: delta9-tetrahydrocannabinol (THC) itself; the synthetic delta9-THC, dronabinol; a 1:1 ratio of delta9-THC:cannabidiol (Sativex); and the synthetic delta9-THC metabolites CT-3 and nabilone. Other Cannabis extracts have also been tested. While 2-3 years ago there was little consensus in the literature, now the majority of studies are beginning to suggest that cannabinoids are useful in the treatment of MS in at least a subset of individuals. Their adverse side-effect profile has generally been mild compared with other drugs used for pain and spasticity; nonetheless, there is still concern about potential long-term side effects, particularly psychiatric side effects and effects on fetal development.
近年来，研究药用大麻素对多发性硬化症（MS）慢性疼痛和痉挛进行对症治疗潜在疗效的临床试验数量急剧增加。已使用了多种不同的大麻素，包括：δ9-四氢大麻酚（THC）本身；合成的δ9-THC，屈大麻酚；δ9-THC与大麻二酚1:1比例的制剂（Sativex）；以及合成的δ9-THC代谢物CT-3和纳布啡。其他大麻提取物也已进行测试。虽然两三年前文献中几乎没有共识，但现在大多数研究开始表明，大麻素至少对一部分个体在治疗MS方面是有用的。与用于疼痛和痉挛的其他药物相比，它们的不良副作用通常较轻；尽管如此，人们仍担心潜在的长期副作用，特别是精神方面的副作用以及对胎儿发育的影响。
